Vermillion's Q3 Net Loss Shrinks on Sharp Cost Cuts | GenomeWeb
NEW YORK (GenomeWeb News) – Vermillion yesterday reported no revenue for its third quarter ended Sept. 30, yet the firm managed to cut its net loss by 27 percent.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.